Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $22.80.

ZVRA has been the topic of a number of research reports. Cantor Fitzgerald cut their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th.

Zevra Therapeutics Trading Down 1.6%

NASDAQ:ZVRA opened at $8.49 on Tuesday. The company has a market capitalization of $477.99 million, a P/E ratio of 18.06 and a beta of 1.08. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16. The firm has a fifty day simple moving average of $8.77 and a 200-day simple moving average of $9.65.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The company had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. On average, equities research analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the company. CWM LLC boosted its holdings in Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after acquiring an additional 1,280 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares during the period. Finally, Creative Planning acquired a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at about $92,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.